N-cadherin is typically expressed in mesenchymal cells and its presence in high-grade tumours is often associated with poorer prognosis, increased metastatic potential and resistance to therapies.40 The upregulation of N-cadherin is often accompanied by the downregulation of E-cadherin, a process known as the cadherin switch, which is associated with tumour progression and metastasis.41 Our data support this claim, as we observed a slight decrease in E-cadherin expression in pT2 HG compared to pT1 HG tumours. The gene discussed is CDH17; the disease is neoplasm.